Table 2 Comparison of case reports on new-onset Graves’ disease during nivolumab therapy
Study | TSH (μIU/mL) | FT3 (pg/mL) | FT4 (ng/dL) | TRAb (IU/L) | TSAb (%) | US | RAIU/ 99mTc uptake | HLA | ||
|---|---|---|---|---|---|---|---|---|---|---|
Before | After | Before | After | |||||||
Iadarola et al. [9] | < 0.01 | 5.71 | 1.36 | NA | Negative | NA | NA | Normal | High (99mTc) | NA |
Brancatella et al. [10] | 0.04 | 7.29 | 2.28 | NA | Negative | NA | NA | Hyper-vascular | High (RAIU) | NA |
Kurihara et al. [11] | 0.008 | 3.88 | 1.72 | NA | Positive (3.7) | NA | NA | Normal | NA | DRB1*04:05 |
Yamada et al. (present case) | < 0.010 | 15.30 | > 5.00 | Negative (< 1.0) | Positive (24.2) | Negative (95) | Positive (2184) | Hyper-vascular | High (99mTc) | DPB1*05:01 |